Tobira is currently enrolling patients in CENTAUR, a global randomized Phase 2 study of CVC vs placebo in patients with NASH and liver fibrosis. For more information about the CENTAUR study, visit www.clinicaltrials.gov, trial identifier NCT02217475.
http://www.tobiratherapeutics.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Saturday
LOAD TIME
0.8 seconds
Tobira Therapeutics, Inc.
Helen Jenkins
400 Oyster●●●●●●●●●● Suite 525
South ●●●●●●ncisco , California, 94080
United States
View this contact
Tobira Therapeutics, Inc.
Helen Jenkins
400 Oys●●●●●●●nt Blvd
South ●●●●●●ncisco , California, 94080
United States
View this contact
Clarke Consulting Incorporated
Matt Clarke
100 Prod●●●●●●●● Suite E
South ●●●●●●ncisco , California, 94080
United States
View this contact
BUY YOUR DOMAIN
17
YEARS
7
MONTHS
1
DAYS
GODADDY.COM, LLC
WHOIS : whois.godaddy.com
REFERRED : http://registrar.godaddy.com
PAGES IN
THIS WEBSITE
0
SSL
EXTERNAL LINKS
11
SITE IP
69.63.140.80
LOAD TIME
0.781 sec
SCORE
6.2
Tobira Therapeutics | CVC for NASH | CENTAUR study | tobiratherapeutics.com Reviews
https://tobiratherapeutics.com
Tobira is currently enrolling patients in CENTAUR, a global randomized Phase 2 study of CVC vs placebo in patients with NASH and liver fibrosis. For more information about the CENTAUR study, visit www.clinicaltrials.gov, trial identifier NCT02217475.
Investor Relations - Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies targeting serious diseases of immune-inflammation and fibrosis. The company’s lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5. CVC is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and has received FastTrack Designation from the FDA. August 17, 2015. August 11, 2015. View all press releases ».
Tobira Therapeutics Announces Initiation of ORION, a Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease (NASDAQ:TBRA)
http://ir.tobiratherapeutics.com/releasedetail.cfm?ReleaseID=927848
Aug 17, 2015. File is in Briefcase. Tobira Therapeutics Announces Initiation of ORION, a Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease. SOUTH SAN FRANCISCO, Calif. Aug 17, 2015. With prediabetes or diabetes and suspected non-alcoholic fatty liver disease (NAFLD). The primary outcome of ORION will measure changes in insulin sensitivity in peripheral and adipose tissue over a 24-week period and will include an interim analysis at 12 weeks. The ORION study will help us ...
frazierhealthcare.afinesite.com
Tobira Therapeutics: A Frazier Healthcare Partners Portfolio Company
http://frazierhealthcare.afinesite.com/portfolio/tobira-therapeutics
Medical Products and Distribution. Targeting serious diseases of immuno-inflammation and fibrosis. Acquired by Allergan in 2016. Bay Area, California. Allergan Successfully Completes Tobira Therapeutics Acquisition. Allergan to Acquire Tobira Therapeutics. Tobira Therapeutics Completes Patient Recruitment for CENTAUR Phase 2b Study of Cenicriviroc in NASH with Liver Fibrosis. Tobira Therapeutics Completes Financing and Merger with Regado Biosciences. 601 Union Street, Suite 3200. Medical Products and Dis...
Tobira Therapeutics Reports Second Quarter 2015 Financial Results (NASDAQ:TBRA)
http://ir.tobiratherapeutics.com/releasedetail.cfm?ReleaseID=927176
Aug 11, 2015. File is in Briefcase. Tobira Therapeutics Reports Second Quarter 2015 Financial Results. Positive Momentum on NASH Clinical Program. Strong Quarter-end Cash Position of $63.7 Million. Conference Call to be Held Today at 4:30 pm Eastern Time. SOUTH SAN FRANCISCO, Calif. Aug 11, 2015. Tobira Therapeutics, Inc. MD, Tobira's chief executive officer. Second Quarter 2015 and Recent Business Highlights. Under the ticker symbol TBRA. Completed patient recruitment in the CENTAUR study. CENTAUR i...
TOTAL LINKS TO THIS WEBSITE
11
とびら of 東京バイオマーカー・イノベーション技術研究組合
とびら of 東京バイオマーカー イノベーション技術研究組合. Ssociation:TOBIRA は産 官 学 医が密接に連携し、有用なバイオ-マーカーを用いて、超早期発見や治療効果予測など次世代の診断やその測定機器の開発、ならびに、これらを迅速に評価ができる臨床研究の整備に取り組み、がん、生活習慣病、感染症、虚血性疾患など多くの疾患の 早診完治 による先進医療都市 東京 の実現を目指しています。 この度、東京バイオマーカーイノベーション技術研究組合 TOBIRA は、オープンイノベーションにより新医療技術および新医療機器の早期実用化を支援する トビラ バイオテクノロジー パートナーズ TOBIRA BioTechnology Partners を設置しました。 TOBIRA BioTechnology Partners seminar.
Tobira Records
Tobira Records new web site is open. Thank you for assistance. Tobira Compilation vol.1 out now. Tobira Compilation vol.1. Available:June 30th, 2011. 01 greg davis "mindmirror". 02 nobuto suda "ephemeral". 03 sean mccann "guardian". 04 ieva "invisible live at cafe indepandant". 05 hakobune "isolated resonance of". 06 celer "remaining open to grace". 07 celer "the thing that makes everything else unimportant". 08 david tagg "guitar and water". 09 brian grainger "bottleneck". 10 richard lainhart "forming".
Tobira Records
Hakobune “A Distant Loss”. Garden Of Ghosts “Garden Of Ghosts”. Hakobune “Recalling My Insubstantial Thoughts”. Saturn Form Essence “Philosophy Of Chaos Structure”. Hakobune “Trace”. Various “Tobira Compilation Vol.1″. Hakobune “Sense Of Place”. Hakobune “Momentarily Endless”. Nobuto Suda “Sensitive Fields”. Garden Of Ghosts “風土”. Somukenai / Learned Helplesness “Split”. Nobuto Suda “Bloom”. Hiroki Sasajima “Crossion”. Richard Lainhart / Hakobune “Untitled”.
Tobira Therapeutics | CVC for NASH | CENTAUR study
Targeting serious diseases of. Our lead product candidate cenicriviroc (CVC) is under evaluation to treat non-alcoholic steatohepatitis (NASH) with liver fibrosis and other serious illnesses. NASH is a severe type of non-alcoholic fatty liver disease, or NAFLD. NASH affects 3 to 5 percent of the US population and can lead to life-threatening complications such as cirrhosis and liver cancer. There are no approved therapies for patients suffering from this severe condition. CVC Development in NASH.
Tobira Therapeutics | CVC for NASH | CENTAUR study
Non-Alcholic Steatohepatitis – A Global Epidemic. Cenicriviroc (CVC) – a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5. Building a leading platform of anti-inflammatory and anti-fibrotic therapies for serious liver disease. We are focused on the development and commercialization of therapies to change the course of the NASH epidemic and other serious liver diseases. Developing Novel Treatments for Chronic Liver Disease. October 20, 2016. October 19, 2016. October 3, 2016.
TobiRawrr (Tobi) - DeviantArt
Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')" class="mi". Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')". Join DeviantArt for FREE. Forgot Password or Username? Deviant for 8 Years. This deviant's full pageview. Last Visit: 331 weeks ago. This is the place where you can personalize your profile! Favouri...
門扉の事なら片倉建鉄へ 門扉 フェンス 電動門扉 手作り門扉 高級門扉 メーカー
門扉 両開き 引き戸 大型門扉 電動門扉 monnpi. カラクラのTOPページ 堅実な門扉の設計施工 デザイン門扉 の総合メーカー 手作り門扉はカタクラで. 1966年 昭和41 6月25日 創業49年. 本 社 神奈川県横浜市神奈川区片倉5丁目2番5号 経理業務. 工 場 神奈川県横浜市神奈川区羽沢町47-4 営業 設計 製作 工事. お問い合わせ番号 ０４５ ３８１ ５５６６ ＦＡＸ０４５ ３８１ ５５６８. 更新日 ( ο )ゝ.
[豆本の扉や]TOP
H t t p : / / t o b i r a y a . n e t /. 店主西イズミが文 絵 製本などの過程をプリンタやPCの力を借りつつ、一冊一冊 手作業で本の形にこさえています。 掲載情報、イベント情報など更新するブログ http:/ tobiraya.net/blog/. 2011年に発売された猫と猫と暮らす人のための本 第２弾の 新装版 が発売されました.
劇団扉座公式サイト～厚木市・市民が一体となったプロジェクトのほか、ワークショップなど様々な活動を展開しています～
また、厚木にて市民 応援団 厚木市文化会館と3者で 厚木シアタープロジェクト を結成。 つか版 忠臣蔵 大願成就討ち入り篇 (2014年). つか版 忠臣蔵 スカイツリー篇 Returns (2013年). 人情噺 端敵 天下茶屋 (2012年). つか版 忠臣蔵 スカイツリー篇 東京 厚木あゆコロ篇 厚木 2012年. LOVE LOVE LOVE 15. LOVE LOVE LOVE R36. 第36回岸田國士戯曲賞 作品名 愚者には見えないラマンチャの王様の裸 を受賞. 第28回大谷賞 作品名 新 三国志 を史上最年少で受賞. ドアクラブ優先予約 扉座へ電話予約のみ 9月12日 土 12:00 18:00. 平日12:00 18:00 平日12:00 18:00 前売開始日以外の土 日 祝休 公演中12:00 16:00 11月5日休. また、厚木にて市民 応援団 厚木市文化会館と3者で 厚木シアタープロジェクト を結成。
